DE vs MRK: Which Is the Better Buy?
Side-by-side comparison of Deere & Company and Merck & Co., Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
Deere & Company · Industrials
$589.24
-29.6% upside to fair value
Grade D
High Quality
VS
Merck & Co., Inc. · Healthcare
$113.87
-12.1% upside to fair value
Grade D
High Quality
QuantHub Verdict
MRK has more upside to fair value
(-12.1%).
MRK trades at a lower forward P/E
(32.0x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DE |
MRK |
| Current Price |
$589.24 |
$113.87 |
| Fair Value Estimate |
$414.61 |
$100.14 |
| Upside to Fair Value |
-29.6%
|
-12.1%
|
| Market Cap |
$159.1B |
$281.2B |
| Forward P/E |
33.3x
|
32.0x
|
| EV / EBITDA |
18.8x
|
17.3x
|
| Price / Sales |
3.4x
|
4.3x
|
| Price / FCF |
42.2x
|
19.9x
|
| Revenue Growth YoY |
+6.7%
|
+4.3%
|
| Gross Margin |
35.4%
|
75.9%
|
| Operating Margin |
18.4%
|
27.6%
|
| Return on Equity |
18.3%
|
17.9%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
2.37%
|
5.02%
|
| Analyst Consensus |
Hold
|
Hold
|
Investment Thesis
Deere & Company is a leading global manufacturer of agricultural, construction, and forestry machinery with a durable competitive moat anchored by its number one market share in large agricultural equipment and a dense dealer network. The company benefits from embedded precision agriculture technology that widens its competitive gap, particularly in North America where it holds 40 to 60 percent m…
Merck & Co., Inc. is a leading global healthcare company specializing in pharmaceuticals, vaccines, and animal health products. Its business quality is high, supported by a durable competitive moat anchored in the dominant global position of Keytruda in PD-1/PD-L1 oncology, a strong vaccines portfolio including Gardasil, and scale in R&D and manufacturing. The company benefits from a seasoned lea…
Accumulation Zones
| Metric |
DE |
MRK |
| Zone Low |
$310.96 |
$75.11 |
| Zone High |
$352.42 |
$85.12 |
| In Buy Zone? |
No
|
No
|